Open Access
Subscription Access
Open Access
Subscription Access
Molecular Docking Identifies Novel Phytochemical Inhibitors Against Sars-cov-2 for Covid-19 Therapy
Subscribe/Renew Journal
SARS-CoV-2 the new strain of SARS corona virus is an RNA virus that inflicts acute respiratory distress syndrome due to infection of the alveolar epithelial cells, its primary target. No effective drug is currently available to treat this viral infection. Therefore, we focused on identifying inhibitors of the main viral protease domain (Mpro) which plays important role in the virus life cycle. Two tired computer-aided drug discovery approach were adopted for screening of novel inhibitors against Mpro, the target protein. First, based on their ADME/T properties, phytochemicals as well as synthetic drugs six compounds were selected from the available database. In second screening by molecular docking based on binding affinity and molecular interactions of these compounds with Mpro led to the identification of the best phytochemical and synthetic compound against Mpro. The result of docking complex showed that, interacting residues for myricetin are continuous while, in case of fosamprenavir, these are non-contiguous. Both molecules interact with the residues in the active site occupying the site for the catalytic activity indicate possible competitive inhibitors of the Mpro.
Keywords
COVID-19, Phytochemical, Anti-viral, therapeutic, docking, ADME/T.
Subscription
Login to verify subscription
User
Font Size
Information
- Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Yuan M. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579: 265-269.
- Bradburne AF, Bynoe ML,Tyrrell DA. . Effects of a" new" human respiratory virus in volunteers. BMJ 1967; 3:767.
- Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K.. Bats and coronaviruses. Viruses 2019; 11:41-44.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y,Cheng, Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020; 39: 497-506.
- B. V. Naresh. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian J. Pharm. Res. 2020; 10;233-238.
- Manisha Rokade, Pradnya Khandagale. Coronavirus Disease: A Review of a New Threat to Public Health. Asian J. Pharm. Res. 2020; 10:241-244.
- Mayur S. Jain, Shashikant D. Barhate. Corona viruses are a family of viruses that range from the common cold to MERS corona virus: A Review. Asian Journal Research Pharmaceutical Science. 2020; 10;204-210.
- R Siva Kumar, Shaik Nafeez Basha, P Kumar Nallasivan, WD Sam Solomon, R Venkatnarayanan. Computer Aided Docking Studies on Antiviral Drugs for Bird Flu. Asian J Res Chem, 2010,3;370-373.
- Jaya Tripathi, Manoj Kumar Mahto, Divya R., Prof. M. Bhaskar, Sajad Shahbazi. Molecular Docking and Toxicity Analysis of Novel Atorvastatin Structural Analogues with HMG-CoA Reductase. Asian Jo Res Chem, 2012;5;386-389.
- Karthik Dhananjayan, Arunachalam Sumathy, Sivanandy Palanisamy. Molecular Docking Studies and in-vitro Acetylcholinesterase Inhibition by Terpenoids and Flavonoids. Asian J Res Chem, 2013; 6; 1011-1017.
- Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A,Wang J. PubChem substance and compound databases. Nucleic Acids Res; 44, 2016, 1202-1213.
- Csizmadia P . MarvinSketch and MarvinView: molecule applets for the World Wide Web. 1999.
- Mangal M. Sagar P, Singh H, Raghava GP, Agarwal SM. NPACT: naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res 2013; 41: 1124-1129.
- Daina A, Michielin O, Zoete V. (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports 2017; 7: 42717.
- Laskowski, R. A., PDBsum new things. Nucleic acids research, 2001; 37; 355-359.
- Norgan AP, Coffman PK, Kocher JPA, Katzmann DJ, Sosa CP. Multilevel parallelization of AutoDock 4.2. J Cheminformatics 2011; 3(1), 12.
- Xu X, Chen P, Wang, J, Feng J, Zhou H, Li X, Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sci 2020; 63: 457-460.
- Sindhu. T. J, Arathi. K. N, Akhilesh K. J, Anju. Jose, Binsiya K. P, Blessy Thomas, Elizabeth Wilson. Antiviral screening of Clerodol derivatives as COV 2 main protease inhibitor in Novel Corona Virus Disease: In silico approaches. Asian J. Pharm. Tech. 2020; 10:60-64.
- Akshay R. Yadav, Shrinivas K. Mohite. A Novel Approach for Treatment of COVID-19 with Convalescent Plasma. Res. J. Pharma. Dosage Forms and Tech.2020; 12:227-230.
- Rut W, Groborz K, Zhang L, Sun X, Zmudzinski M, Hilgenfeld R, Drag, M.Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design. bioRxiv. 2020.
- Hurst KR, Kuo L, Koetzner CA, Ye R, Hsue B, Masters PS. A major determinant for membrane protein interaction localizes to the carboxy-terminal domain of the mouse coronavirus nucleocapsid protein. J Virol 2005; 79(21): 13285-13297.
- Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Dis Today 2020;
- Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto, S. Potential Inhibitor of COVID-19 Main Protease (M pro) from Several Medicinal Plant Compounds by Molecular Docking Study. Preprint 2020.
- Meng Y, Su A, Yuan S, Zhao H, Tan S, Hu C, Guo, Y. Evaluation of total flavonoids, myricetin, and quercetin from Hovenia dulcis Thunb. as inhibitors of α-amylase and α-glucosidase. Plant Foods Human Nutr 2016;71: 444-449.
- Becker S, Thornton L. (2004).Fosamprenavir: advancing HIV protease inhibitor treatmen options. Expert Opin Pharmacother 2004; 5(9); 1995-2005.
Abstract Views: 103
PDF Views: 0